1 SESSION 7: PRECLINICAL & TOXICOLOGY MODELS IN IMMUNO-ONCOLOGY Challenges in the evaluation of preclinical toxicology in immuno-oncology Belén Gracia Moneva Spanish Medicines and Healthcare Products Agency AEMPS Innsbruck, 21 October 2016
2 Disclaimer The views and opinions expressed in the following PowerPoint slides are those of the individual presenter and should not be attributed to the Spanish Medicines and Healthcare Products Agency (AEMPS) or European Medicines Agency (EMA)
3 Immunological treatment options -Monoclonal antibodies -Proteins of immunological control -Adoptive cellular therapy -Cytokines -Others
5 Targets PD-1 Nivolumab- monoclonal antibody anti- PD-1 metastatic melanoma, non-small cell lung cancer and advanced renal carcinoma Pembrolizumab monoclonal antibodyanti-pd-1 metastatic melanoma, lung cancer
6 Targets Signaling lymphocytic activation molecule F7 (SLAMF7) Anti-SLAMF7 antibody, elotuzumab, for multiple myeloma (MM). Receptor present on immune cells, including NK cells. It is also expressed on MM cells. Killer Cell Immunoglobulin Like Receptor (KIR) Anti-KIR antibodies prevents a tolerogenic interaction and augments NK-cell spontaneous cytotoxicity Tumor necrosis super family receptors (TNFRSF) Agonistic antibodies of TNFRSF family of costimulatory receptors (CD134, CD137, etc) predominantly expressed by T-lymphocytes, NKTcells, NK cells and neutrophils that generates an anti-tumor response
7 Targets T-lymphocyte associated antigen-4 (CTLA-4) Anti-CTLA-4-Ipilimumab- anticytotoxic T-lymphocyte associated antigen-4 (CTLA-4) mab approved for the treatment of metastatic melanoma
8 NON-CLINICAL SAFETY ASSESSMENT Guideline S9 on Non-clinical evaluation for anticancer pharmaceuticals in man (EMA/CHMP/ICH/646107/2008) & Q/A doc EMA/CHMP/ICH/453684/2016 This guideline aims to facilitate and accelerate the development of anticancer pharmaceuticals and to protect patients from unnecessary adverse effects, while avoiding unnecessary use of animals, in accordance with the 3R principles (reduce/refine/replace), and other resources.
9 But also, Guideline S6 (R1) on Preclinical safety evaluation of biotechnology-derived pharmaceuticals (EMA/CHMP/ICH/731268/1998) intended to provide general principles for designing scientifically acceptable preclinical safety evaluation programs. 1) to identify an initial safe dose and subsequent dose escalation schemes in humans; 2) to identify potential target organs for toxicity and for the study of whether such toxicity is reversible; and 3) to identify safety parameters for clinical monitoring.
10 Monoclonal antibodies- the immunological properties of the antibody should be described in detail (antigenic specificity, toxicity towards human tissues distinct from the intended target ). Induction of antibody formation in animals is not predictive of a potential for antibody formation in humans. Use of relevant species in safety evaluation programs
11 And, Non-Clinical Safety Studies For The Conduct Of Human Clinical Trials For Pharmaceuticals (ICH M3[R2]) International standards for, and promote harmonisation of, the nonclinical safety studies recommended to support human clinical trials of a given scope and duration as well as marketing authorization for phcals. This guidance should facilitate the timely conduct of clinical trials, reduce the use of animals in accordance with the 3R (reduce/refine/replace) principles and reduce the use of other drug development resources. For biotech products, nc safety package in accordance with ICH S6, M3 only provides guidance with regard to timing of nc studies relative to clinical development.
12 And, Strategies to identify and mitigate risks for first-inhuman clinical trials with investigational medicinal products (EMEA/CHMP/SWP/28367/07) This document addresses non-clinical issues for consideration prior to the first administration of an investigational medicinal product in humans.
13 Others, CHMP/SWP/169215/05 Aug 2008 Need for Non- Clinical Testing in Juvenile Animals on Human Pharmaceuticals for Paediatric Indications Medicinal products under development for specific paediatric indications or in life-threatening or serious diseases without current effective therapies warrant a case-by-case approach. In some cases, some studies may then be adapted, deferred or omitted ICH S10-Photosafety evaluation of pharmaceuticals- Concept paper Jan 2008
14 Guideline S9 on non-clinical evaluation for anticancer pharmaceuticals in man (EMA/CHMP/ICH/646107/2008) 1) Identify the pharmacologic properties of a pharmaceutical 2) Establish a safe initial dose level for the first human exposure and, 3) understand the toxicological profile of a pharmaceutical (identification of target organs, exposure-response relationship, and reversibility). Acceptable safety in humans
15 1) Identify the pharmacologic properties of a pharmaceutical and safety pharmacology Assessment of the pharmaceutical s effect on vital organ functions including cardiovascular, respiratory and central nervous systems available before the initiation of clinical studies. Could be included in general toxicology studies. In the absence of a specific risk, such studies will not be called for to support clinical trials or for marketing.
16 2) Dose selection- LDT and MTD (CLASSIC) The recommended human starting dose is determined by considering all available nonclinical toxicology and pharmacology data. Two approaches: -1 HNSTD-highest non-severely toxic dose from 1-month repeat-dose toxicity study in animal species.--- 1/6 HNSTD---FIH STD10-1/10 the severely toxic dose in 10% animals (STD10) small molecules NOAEL not essential -2 Pharmacology data---percentage of tumour regression plateau mg/kg, Cmax and AUC. Biopharmaceuticals with immune agonistic properties-minimally anticipated biologic effect level (MABEL) should be considered No MAJOR CONCERN IN CALCULATION SAFE STARTING DOSE
17 Dose levels in these clinical studies often are close to or at the adverse effect dose levels Type, timing and flexibility called for in the design of nonclinical studies of anticancer pharmaceuticals can differ from those elements in nonclinical studies for other pharmaceuticals.
18 3) Understand the toxicological profile of a pharmaceutical (identification of target organs, exposure-response relationship, and reversibility). Primary objective of a Phase I clinical trial in patients with advanced cancer is to assess the safety: MTD and DLT. Duration of non-clin studies: 28 days (Phase I,II), 3 months (Phase III) In case of biopharmaceuticals, ---S6 Assessment of the potential to recover from toxicity should be provided to understand the reversibility/irreversibility (1sp) Relevant animal species Immunotoxicological evaluation-immunostimulation, supression, autoimmunity
19 In general, the non-clinical data to support Phase I and the clinical Phase I data would normally be sufficient for moving to Phase II and into a second or first line therapy in patients with advanced cancer.
20 SESSION 7: Other non-clinical data: -Pharmacokinetics in the animal species used for non-clin studies -Reproduction toxicology Embryofetal toxicity studies of anticancer pharmaceuticals should be available when the marketing application is submitted but not essential to support clinical trials in advanced cancer or when are genotoxic or known to cause developmental toxicity. Effects on embryogenesis --Efforts to prevent pregnancy during treatment. Fertility and early embryonic development and pre and postnatal toxicology studies are not warranted in case patients with advanced cancer.
21 -Genotoxicity Not essential for clinical trials in advanced cancer -Carcinogenicity Not essential for clinical trials and marketing in advanced cancer. -Photosafety Phase I (photochemical properties)-photosafety protective measures in CT -Immunotoxicity Specific studies
22 LIMITATIONS -In species-specific cross-reactivity: Lack of relevant animal species in which to conduct toxicological studies- toxicity not predictive for human situation. Non recognition of proteins from other different species than human. The nonclinical safety package consists primarily of in vitro safety and in vivo biological activity assessments. Valuable for nontarget effects. Surrogate animal model -Immunogenicity: ADAs not predictive for human situation -Immune-related adverse events (iraes): Proliferation or cytokine release novel exploratory in vitro cellular proliferation and cytokine release assays. Predictive models?
23 Combination therapies -Well-studied individually in toxicology evaluations. -Rationale for the combination -In general, toxicology studies investigating the safety of combinations of pharm in advanced cancer are not warranted but, -if at least one of these compound is in early stage development (human toxicity profile has not been characterised) a pharmacology study to support the rationale for the combination should be provided that evidence an increased activity in the absence of a substantial increase in toxicity on the basis of limited safety endpoints (mortality, clinical signs, weight gain).
24 Non-clinical studies to support CT in pediatric population Juvenile animals are not usually conducted in order to support inclusion of pediatric populations for the treatment of cancer Only when human safety data and previous animal studies are considered insufficient for safety evaluation in the intended pediatric age group.
25 Ipilimumab -In vitro, ipilimumab binds to human CTLA-4 with high affinity. Ipilimumab did not show cross-reactivity with or binding to CTLA-4 from rats, mice or rabbits, but showed specific binding to cynomolgus monkey recombinant CTLA-4 and activated T-cells. Pharmacological activity only in primates -Safety pharmacology programme (CVS, NS, RS) : in pivotal toxicity studies in monkeys for up to 6 months. No major findings involving safety pharmacology endpoints
26 Ipilimumab -Toxicology: The cynomolgus monkey was selected as the toxicology species in single and repeat dose studies for up to six months because ipilimumab binds specifically to macaque CTLA-4, but not to homologous CTLA-4 in other traditional toxicology species and has pharmacologic activity only in primates. Well tolerated with different immune-related adverse events (iraes) of low incidence linked with the intended pharmacologic basis of CTLA-4 blockade Immunotoxicity assessed in repeat dose tox studies- expected effects due to pharmacological action. Antigenicity: Non significantly inmunogenic in monkeys -Genotoxicity, carcinogenicity, reproduction toxicity : not conducted
27 Nivolumab -Preclinical toxicity conducted in monkey- similarities in tissue binding profiles between cynomolgus monkeys and humans indicate that is an appropriate animal model.rat and rabbit- no-binding -Specific safety pharmacology studies were limited to a single-dose CVS safety study in Cynomolgus monkeys. Supported by ICH guidelines S6(R1), S7A, and S9.
28 Nivolumab -Toxicology: Repeat toxicity studies-1 and 3-month iv in monkeys.well tolerated Changes in immune cell parameters were observed, demonstrating that nivolumab elicited pharmacological responses in healthy monkeys. -Genotoxicity, carcinogenicity, fertility and early embryonic development not conducted-supported according to Guidelines Embryofoetal toxicity in eppnd study -No dedicated local tolerance studies conducted -No general nonspecific immunostimulatory or autoimmune-related toxicities were observed. -ADAs were detected in 67% monkeys receiving monthly doses of nivolumab
29 -No submitted studies for genotoxicity, carcinogenicity as well as fertility and early embryonic development. Pembrolizumab -The pharmacology of pembrolizumab was evaluated in Cynomolgus monkey as the similarities in binding affinities with human PD-1 were observed in in vitro experiments compared to mouse, rat and dog, where no binding was observed. -Stand-alone studies evaluating safety pharmacology of pembrolizumab were not submitted (assessed in tox studies) -No non-clinical dedicated pharmacodynamic drug-drug interactions studies with pembrolizumab were submitted. -The toxicity of pembrolizumab was evaluated in a 1-month and a 6-month repeat-dose study in cynomolgus monkeys. Well tolerated and the NOAEL in both studies was the highest dose tested.
30 Elotuzumab -Elotuzumab only recognizes human SLAMF7 protein. -Because elotuzumab does not recognize non-human forms of SLAMF7 protein, in vivo safety data from animal studies are irrelevant. In the same line, no carcinogenicity data are available for elotuzumab in animals, nor were fertility and embryo foetal toxicity studies performed. Non clinical safety information primarily consists of limited in vitro human cell/tissue studies where no safety findings were identified. -Clinical trials data were therefore an important source of information to support the safety in patients.
31 CONCLUSIONS - Relevant animal model- poor predictive toxicology-limited data - Immunogenicity non-predictive data - Immune-related adverse events (iraes) assessment nonpredictive data - New complex combinations limited data Risk mitigation strategies should be adopted for CT
33 CONCLUSIONS CLASSIC CYTOTOXIC THERAPY TOXICOLOGY DATA PHARMACOLOGICAL DATA Careful monitoring of patients adverse effects
34 CONCLUSIONS IMMUNOTHERAPY PRODUCTS PHARMACOLOGY DATA TOXICOLOGY DATA Careful monitoring of patients immune function
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE NONCLINICAL EVALUATION FOR ANTICANCER PHARMACEUTICALS
May 2010 EMA/CHMP/ICH/646107/2008 ICH guideline S9 on nonclinical evaluation for anticancer pharmaceuticals Step 5 Transmission to CHMP December 2008 Adoption by CHMP for release for consultation December
Guidance for Industry S9 Nonclinical Evaluation for Anticancer Pharmaceuticals U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center
AOQ-Qld RRDM seminar 2 July 2008 Preclinical Safety Studies of Experimental Medicines Brian Creese (firstname.lastname@example.org) Introduction Seminar Outline Preclinical safety data requirements for phase
European Medicines Agency Pre-authorisation Evaluation of Medicines for Human Use London, 29 September 2005 Doc. Ref. EMEA/CHMP/SWP/169215/2005 COMMITTEE FOR HUMAN MEDICINAL PRODUCTS (CHMP) DRAFT GUIDELINE
First Dose in Humans Dr John Donohoe Clinical Trial Guidelines - ICH ICH M3 Non-clinical safety studies for the conduct of clinical trials for pharmaceuticals (Original 1996, R1 2000, R2 draft 2008) ICH
ICH M3 (R2) Guideline on Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals International Conference on Harmonisation of Technical Requirements
L1 Session 6 Clinical Trial Assessment Phase I Clinical Trial Presentation to APEC Preliminary Workshop on Review of Drug Development in Clinical Trials Celia Lourenco, PhD, Manager, Clinical Group I Office
Guidance for Industry M3 Nonclinical Safety Studies for the Conduct of Human Clinical Trials for Pharmaceuticals July 1997 ICH Guidance for Industry M3 Nonclinical Safety Studies for the Conduct of Human
IBE Clinical Epidemiology Drug Development I Preclinical Development Sascha Tillmanns, MSc, Medical Director email@example.com Clinical/Preclinical Development, SuppreMol GmbH Agenda Scope Introduction
European Medicines Agency November 2000 CPMP/ICH/286/95 ICH Topic M 3 (R1) Non-Clinical Safety Studies for the Conduct of Human Clinical Trials for Pharmaceuticals Step 5 NOTE FOR GUIDANCE ON NON-CLINICAL
There are five (5) modules in CTD. LAYOUT OF CTD COMMON TECHNICAL DOCUMENT - EU THESE FIVE ARE: MODULE 1 - ADMINISTRATIVE MODULE 2 OVERALL SUMMARIES MODULE 3 - QUALITY MODULE 4 NON CLINICAL STUDY REPORTS
The European Agency for the Evaluation of Medicinal Products Human Medicines Evaluation Unit London, 23 July 1998 COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) NOTE FOR GUIDANCE ON THE PRE-CLINICAL
How Much Animal Data are Required to Move into Clinical Testing? Hilary Sheevers, PhD Aclairo October 10, 2007 Guidances FDA is Guidance Driven Good news: guidances are on FDA s website ICH M3 for small
December 2009 EMA/CPMP/ICH/286/1995 ICH guideline M3(R2) on non-clinical safety studies for the conduct of human clinical trials and marketing authorisation for pharmaceuticals Step 5 Transmission to CHMP
Antibody-Drug Conjugates: what are the data telling us? A retrospective review with emphasis on human starting dose Haleh Saber, Ph.D. Supervisory Pharmacologist Office of Hematology and Oncology Products
Preclinical safety test strategy for New Biological Entities (NBEs) Regulatory toxicology workshop München 2005 General principles Develop strategy on a case by case basis Close interaction with regulatory
Safety Pharmacology Federal Institute for Drugs and Medical Devices (BfArM), Germany SAFETY PHARMACOLOGY Scope Guideline is applied generally to New chemical and biological entities, including biotechnology-derived
Anti-Drug Antibody Testing In Toxicity Studies Part 1: Scientific Background and Regulatory Expectation Danuta Herzyk Safety Assessment Merck Research Laboratories 1 Outline The immune response to biological
Aurigon Life Science GmbH Non-clinical development of biologics Requirements, challenges and case studies Committed to Life. Sigrid Messemer vet. med. M4 Seminar March 10 th 2014 Aurigon - your full service
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE GUIDELINE ON THE NEED FOR CARCINOGENICITY STUDIES
NCT02020291 Preliminary Report: Phase I Dose Escalating Study to Evaluate the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Profiles of Foxy-5 in Patients with Metastatic Breast, Colon or Prostate
European Medicines Agency July 2008 CPMP/ICH/286/95 ICH Topic M 3 (R2) Non-Clinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals Step 3 NOTE FOR
June 2011 EMA/CHMP/ICH/731268/1998 Committee for medicinal products for human use (CHMP) ICH guideline S6 (R1) preclinical safety evaluation of biotechnology-derived pharmaceuticals Step 5 Part I (Parent
Risk Assessment of Novel Biopharmaceutical Platforms Mary Jane Hinrichs, PhD Types of Novel Biopharmaceutical Platforms Targeted nanoparticles Bispecifics Antibody Drug Conjugates Fc-mutated mabs ICHS6(R1)
DESIGN & ENDPOINT OF PHASE I / TRANSLATIONAL RESEARCH MONDAY 7 TH JULY 2014 UZMA RAYANI CLINICAL OPERATIONS MANAGER Drug Development Office 100 DRUG DEVELOPMENT AND OPERATIONAL STAFF NEW AGENTS IN CLINICAL
PreClinical Safety (PCS) Consultants Ltd AGAH WORKSHOP Critical Aspects of Integrated Drug Development - Expect the Unexpected! 28. - 29. November 2014, Munich Non-Clinical Development of Oncology Medications
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE PRECLINICAL SAFETY EVALUATION OF BIOTECHNOLOGY-DERIVED
European Medicines Agency July 1996 CPMP/ICH/140/95 ICH Topic S 1 A The Need for Carcinogenicity Studies of Pharmaceuticals Step 5 NOTE FOR GUIDANCE ON THE NEED FOR CARCINOGENICITY STUDIES OF PHARMACEUTICALS
Immunogenicity of mabs Industry perspective AM Autere, Roche, May 2010 Background Experience on industry commenting on the recent regulatory guidance documents related to immunogenicity&mabs EMA CONCEPT
Requirements for the First-In In-Human Clinical Trials David R Jones (David.Jones@mhra.gsi.gov.uk) Expert Scientific Assessor (Pharmacotoxicologist), Licensing Division, Medicines and Healthcare products
+ Anti-PD1 Agents: Immunotherapy agents in the treatment of metastatic melanoma Claire Vines, 2016 Pharm.D. Candidate + Disclosure I have no conflicts of interest to disclose. + Objectives Summarize NCCN
L1 4.1 Objectives of Clinical Trial Assessment Presentation to APEC Preliminary Workshop on Review of Drug Development in Clinical Trials Celia Lourenco, PhD, Manager, Clinical Group I Office of Clinical
1 2 3 4 21 July 2016 EMA/CHMP/CVMP/JEG-3Rs/677407/2015 Committee for Medicinal Products for Human Use (CHMP) Committee for Medicinal Products for Veterinary Use (CVMP) 5 6 7 8 9 Review and update of EMA
Biologics and Manufacturing Changes Richard M. Lewis, PhD and Mary Ellen Cosenza, PhD, DABT, RAC 24 Historically, biological products were defined by the process that produced them. Biochemical methods
Safeguarding public health UK Experiences with Exploratory Clinical Trials David R Jones Expert Scientific Assessor (Pharmacotoxicologist), Licensing Division, Medicines and Healthcare products Regulatory
Basic Overview of Preclinical Toxicology Animal Models Charles D. Hebert, Ph.D., D.A.B.T. December 5, 2013 Outline Background In Vitro Toxicology In Vivo Toxicology Animal Models What is Toxicology? Background
LGD 6972: Glucagon Receptor Antagonist Highly Potent, Orally Bioavailable, Small Molecule Glucagon Receptor Antagonist for the Treatment of Type 2 Diabetes Overview Diabetes is one of the largest and fastest
M3(R2) Implementation Working Group M3(R2) Guideline: Guidance on Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals Questions & Answers
Biological importance of metabolites Safety and efficacy aspects Bernard Walther Technologie Servier Biological importance of metabolites Safety testing of drug metabolites Bioanalytical strategy Structural
Guidance for Industry M3(R2) Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals U.S. Department of Health and Human Services Food and Drug
Preclinical Development to IND: Drugs and Vaccines Maralee McVean, PhD Vice President, Pharmacology and Toxicology Services PreClinical Research Services, Inc. firstname.lastname@example.org Overview
GUIDELINE ON SAFETY PHARMACOLOGY STUDIES FOR HUMAN PHARMACEUTICALS (S7A) ICH S7 Expert Working Group M. Hashimoto Ph.D. Pharmacia Efficacy Guideline on Safety Pharmacology Studies Safety ICH-CTD Definition:
8th OPEN SCIENTIFIC EIP SYMPOSIUM ON IMMUNOGENICITY OF BIOPHARMACEUTICALS Draft EMA immunogenicity guideline Vilamoura 22-24.5.2016 Pekka Kurki Finnish Medicines Agency EMA The views and opinions expressed
MEDICINES CONTROL COUNCIL BIOSIMILAR MEDICINES QUALITY, NON-CLINICAL AND CLINICAL REQUIREMENTS This guideline is intended to provide recommendations to applicants wishing to submit applications for the
Immuno-Oncology: Harnessing the Oncologist That Lies Within A Patient s Immune System Kevin P. Hubbard, DO, FACOI Interim Chair - Department of Specialty Medicine Professor and Chair - Division of Internal
European Medicines Agency June 1995 CPMP/ICH/384/95 ICH Topic S 3 A Toxicokinetics: A Guidance for Assessing Systemic Exposure in Toxicology Studies Step 5 NOTE FOR GUIDANCE ON TOXICOKINETICS: A GUIDANCE
RADIOPHARMACEUTICALS BASED ON MONOCLONAL ANTIBODIES Guideline Title Radiopharmaceuticals based on Monoclonal Antibodies Legislative basis Directives 65/65/EEC, 75/318/EEC as amended, Directive 89/343/EEC
European Medicines Agency Evaluation of Medicines for Human Use London, 22 February 2006 EMEA/CHMP/BMWP/31329/2005 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) ANNEX TO GUIDELINE ON SIMILAR BIOLOGICAL
Protocol Development, Design and Analysis of Phase 1 Clinical Trials in Cancer Therapy November 2016 S. Gail Eckhardt, M.D. Professor of Medicine/Oncology Director, Phase I Program University of Colorado
Financial disclosure AJM van den Eertwegh Advisory board - BMS, GSK, Roche, Merck, Pfizer Speakers fee -BMS Immunotherapy is also targeted therapy Fons van den Eertwegh, medical oncologist Targeted therapy
18 March 2010 EMEA/CHMP/BMWP/301636/2008 Corr.* Committee for Medicinal Products for Human Use (CHMP) Guideline on non-clinical and clinical development of similar biological medicinal products containing
1 2 Lecture outline Immunological tolerance and immune regulation -- 1 Abul K. Abbas UCSF Principles of immune regulation Self-tolerance; mechanisms of central and peripheral tolerance Inhibitory receptors
Clinical: Ipilimumab (MDX-1) Data Highlights Jeffrey S. Weber, M.D., Ph.D. Chief of Oncology Keck School of Medicine at the University of Southern California R&D Day December 9, 25 Obstacles to Successful
Non Clinical Development for ATMP: In Vivo Study Requirements and Strategy in Absence of Relevant Models Swissmedic Overview 1. Swiss Regulatory Basis for GT/GMO Products and TpPs 2. General Strategies
Guidance for Industry Safety Testing of Drug Metabolites U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) February 2008 Pharmacology
European Medicines Agency London 23 April 2009 EMEA/CHMP/BMWP/102046/2006 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) REFLECTION PAPER NON-CLINICAL AND CLINICAL DEVELOPMENT OF SIMILAR MEDICINAL
HOW DO I GET MY COMPOUND INTO PHASE I? Considerations For Program Design: Various Scenarios And Approaches By Dr. Scott E. Boley and Greg Ruppert PREFACE The primary challenge for pharmaceutical and biotechnology
Introduction To Clinical Research and Drug Discovery Process Drug Discovery Process Pre-clinical Development Clinical Development Drug Discovery Process Process of generating a new idea that is targeted
Cancer Immunotherapy: Can Your Immune System Cure Cancer? Steve Emerson, MD, PhD Herbert Irving Comprehensive Cancer Center Bodnar s Law Simple Things are Important Very Simple Things are Very Important
21 July 2016 EMA/CHMP/BWP/271475/2006 rev.1 Committee for medicinal products for human use (CHMP) Guideline on potency testing of cell based immunotherapy medicinal products for the 3Rs technical update*
NEW CLINICAL RESEARCH OPTIONS IN PANCREATIC CANCER IMMUNOTHERAPY Alan Melcher Professor of Clinical Oncology and Biotherapy Leeds CANCER IMMUNOTHERAPY - Breakthrough of the Year in Science magazine 2013.
European Medicines Agency Evaluation of Medicines for Human Use London, 10 October 2007 Doc. Ref. COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON POTENCY TESTING OF CELL BASED IMMUNOTHERAPY
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE SAFETY PHARMACOLOGY STUDIES FOR HUMAN PHARMACEUTICALS
ews in onclinical Evaluation of Anticancer Pharmaceuticals: ICH guideline S9 and beyond Wissenschaftliche Prüfungsarbeit zur Erlangung des Titels Master of Drug Regulatory Affairs der Mathematisch-aturwissenschaftlichen
THE ASEAN COMMON TECHNICAL DOSSIER (ACTD) FOR THE REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE PART III: NONCLINICAL DOCUMENT PREAMBLE THE ASEAN COMMON TECHNICAL DOSSIER (ACTD) FOR THE REGISTRATION OF
Testing Services for Large Molecule Drug Development Our mission is to extend our clients capabilities by combining scientific knowledge, capacity, regulatory expertise and flexibility to provide the trusted,
An active immunotherapy combined with first-line weekly paclitaxel in metastatic breast cancer: first results of IMP321 (LAG-3Ig) as an antigen presenting cell activator in the AIPAC phase IIb trial Frédéric
Integrated Biosimilar Services 30+ Studies covering early phase and phase III With you every stage of the process A promising and evolving market 7 out of 10 of the best selling drugs in 2015 were biologics.
GENETIC PROFILES AND TARGETED TREATMENT OF CANCER - PERSONALIZED MEDICINE Branko Zakotnik MD, PhD Department of Medical Oncology Institute of Oncology Ljubljana 1 I have no conflict of interest to declare
The immune system Basophil Neutrophil Bone marrow Eosinophil Myeloid progenitor Dendritic cell Pluripotent Stem cell Lymphoid progenitor Platelets Bone marrow Thymus NK cell T-cell B-cell Spleen Cancer
Monoclonal Antibodies as Drugs Charles G. Drake M.D. / Ph.D. Associate Professor: Medical Oncology, Immunology and Urology Johns Hopkins Kimmel Cancer Center Presenter Disclosure Information Charles G.
Introduction to Immunotherapy in Bladder Cancer Jason A. Efstathiou, M.D., D.Phil. Associate Professor of Radiation Oncology Massachusetts General Hospital Harvard Medical School BCAN Bladder Cancer Think
Non-Rodent Selection in Pharmaceutical Toxicology A Points to Consider document, developed by the ABPI in conjunction with the UK Home Office DAVID SMITH Animal Research & Welfare Advisory Group PAUL TRENNERY
Immunotherapy and the Future of Cancer Therapy Charles G. Drake MD / PhD Professor: Medical Oncology, Immunology and Urology Co-Director: Division of Immunology Co-Director: Multi-Disciplinary Prostate
European Medicines Agency London, 21 February 2008 Doc. Ref. EMEA/CHMP/SWP/488313/2007 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) DRAFT GUIDELINE ON REPEATED DOSE TOXICITY DRAFT AGREED BY SAFETY
COMPANY PRESENTATION JEFFERIES HEALTHCARE CONFERENCE JUNE 2015 FORWARD LOOKING STATEMENT This document has been prepared by Innate Pharma S.A. (the Company ) solely for the purposes of a presentation to
The European Agency for the Evaluation of Medicinal Products Evaluation of Medicines for Human Use London, 27 July 2000 COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) NOTE FOR GUIDANCE ON REPEATED
Targeted Chemotherapy: Guiding patients to more personalized care Anna Hitron, Pharm.D, MS, MBA, BCOP Oncology Pharmacy Specialist Baptist Health Louisville September 10, 2015 Objectives Discuss the role
Biologics: Specific Drug Safety Challenges Violetta B. Kyburz 2012 2013 2014 Biologics: Specific Drug Safety Challenges Topics for discussion Particular issues in the preclinical development of biologics
Quality & Compliance A First-in-Man Phase 1 Clinical Trial A Tragic Ending leads to a New Guideline Research Subject Safety Series Part 1 By Lorna Speid, PhD, RAC The injury of six healthy volunteer research